Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

4(80.0%)

N/A

1(20.0%)

5Total

Phase 4(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05384483Phase 4Completed

Cariprazine Versus Placebo for Social Anxiety Disorder

Role: lead

NCT02473419Completed

Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

Role: collaborator

NCT01316302Phase 4Completed

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

Role: lead

NCT02294305Phase 4Unknown

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

Role: lead

NCT01712321Not ApplicableUnknown

Study of Vilazodone to Treat Social Anxiety Disorder

Role: lead

NCT00237666Phase 4Completed

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

Role: lead

All 6 trials loaded